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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effectiveness of antibiotics compared to a control (no treatment or placebo) for persistent respiratory symptoms
following acute bronchiolitis (within six months).
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B A C K G R O U N D
Description of the condition
Bronchiolitis is a common acute respiratory infectious condition,
with a high prevalence worldwide (Chang 2009). It is a clinically
diagnosed syndrome manifested by tachypnoea (rapid breathing)
with crackles or wheeze in very young children. Multiple viruses
and some bacteria can cause bronchiolitis, including respiratory
syncytial virus, influenza, human metapneumovirus, rhinovirus,
influenza, parainfluenza, adenovirus, and mycoplasma.
In the acute phase (< 14 days), antibiotics have only been rec-
ommended in the treatment of bronchiolitis when a secondary
bacterial infection is suspected. In acute bronchiolitis, a Cochrane
review (Spurling 2011) found “minimal evidence to support the
use of antibiotics for acute bronchiolitis”.
Although bronchiolitis is usually a self-limiting condition, typi-
cally lasting from three to seven days, a number of children con-
tinue to display respiratory symptoms following acute bronchioli-
tis. Swingler 2000 reported that 39% of infants were still symp-
tomatic after 14 days, 18% after 21 days and 9% after 28 days.
(Swingler 2000). Other studies have shown that 40% to 50% of
those hospitalised have a “grumbling, sometimes protracted, res-
piratory syndrome of persistent cough and recurrent viral-induced
wheeze” (SIGN2006).While symptoms such as cough andwheez-
ing in post-acute bronchiolitis may be mild, they have the poten-
tial to increase burden of disease and some children present or re-
present to secondary care. Furthermore, in some settings, recur-
rent hospitalisations for bronchiolitis are common (Bailey 2009),
thus increasing the burden (morbidity, social, economic, etc.) of
disease. Also, cohort studies have suggested that bronchiolitis may
trigger the development of asthma (Sigurs 2000; Carroll 2009).
The possible biological mechanism giving rise to the persistent
respiratory symptoms are likely multifactorial. In bronchiolitis,
airway oedema occurs, the airway epithelium is affected and the
cilial damage can persist for 13 to 17 weeks (Wong 2005). Cilia
are an important component of the airway’s clearance mechanism.
Damage of airway cilia and the possible impairment of the in-
nate immunity in severe bronchiolitis (Halfhide 2008) predisposes
these infants to secondary bacterial infection. Persistent or delayed
resolution of airway oedema, or secondary bacterial infection in
the airways (endobronchial infection) related to persistent cilial
damage can cause wheeze, cough or both.
Description of the intervention
In the presence of endobronchial infection, antibiotics are a poten-
tially beneficial intervention for post-acute bronchiolitis. Antibi-
otics may be given orally, intravenously, or via nebuliser. The effi-
cacy of antibiotics in the acute or non-acute phase may be possibly
influenced by study setting. For example, in non-affluent settings
where bacterial colonisation of the nasopharynx is higher than in
affluent urban settings (Leach 1994), antibiotics are possibly more
effective when dense bacterial load is present in the upper airways.
How the intervention might work
Antibiotics may be useful in treating the symptoms of post-acute
bronchiolitis, by eliminating the secondary bacterial infection in
the airways. Lower airway bacterial infection following viral res-
piratory infection has been well described in airway cells in vitro
(Didierlaurent 2008), as well as in clinical studies (McCullers
2006).
In addition to an antibacterial effect, the anti-inflammatory
properties of antibiotics, such as macrolides, may have an ad-
ditional effect through its immunomodulatory effect and in-
fluence on neutrophilic inflammation (Giamarellos-Bourboulis
2008; Zarogoulisidis 2011), thus reducing airway oedema.
Elimination of the endobronchial infection and/or inflammation,
may reduce airway secretions and/or oedema, and thus conse-
quently improve the persistent respiratory symptoms.
Why it is important to do this review
A small but not insignificant number of children with acute bron-
chiolitis have persistent problems after the acute viral infection (for
a variety of reasons) and these children are usually seen in secondary
and tertiary practice. This group of children are clinically treated
with a variety of medications such as antibiotics, bronchodila-
tors, inhaled (Fox 1999) and oral corticosteroids (Blom-Danielle
2007), and leukotriene receptor antagonists (Kim 2010). This
clinical issue has been identified as an area that needs more re-
search (SIGN 2006). Further, use of any medications may result
in adverse events, and persistence of symptoms also influence bur-
den of disease and health economics. Thus, a systematic review
of the benefits, or otherwise, of using antibiotics in the post-acute
bronchiolitis phase will be useful to guide clinical practice.
O B J E C T I V E S
To determine the effectiveness of antibiotics compared to a con-
trol (no treatment or placebo) for persistent respiratory symptoms
following acute bronchiolitis (within six months).
M E T H O D S
Criteria for considering studies for this review
2Antibiotics for persistent cough or wheeze following acute bronchiolitis in children (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Types of studies
All randomised controlled trials (RCTs) comparing antibiotics
with controls (placebo or no treatment) given in the post-acute
phase of bronchiolitis.
Types of participants
Inclusion criteria: previously well children (aged < 2 years) with
bronchiolitis (as defined by study authors) who have been treated
with antibiotics beyond the acute bronchiolitis period (>14 days).
Exclusion criteria: children with any underlying chronic disease
such as lung disease (cystic fibrosis, bronchopulmonary dysplasia,
bronchiectasis, aspiration,etc.), cardiac disease, and immunodefi-
ciency (primary or secondary).
Types of interventions
All types of antibiotics, given beyond the acute period (>14 days).
This includes antibiotics prescribed for acute bronchiolitis that
goes beyond the acute phase of 14 days.
Types of outcome measures
Primary outcomes
1. Proportion of participants who were not cured at follow-up
(up to six months).
2. Proportion readmitted for a respiratory illness within six
months.
We will determine the proportion of participants who failed to im-
prove on treatment (antibiotics or placebo), and the mean clinical
improvement, using the following hierarchy of assessment mea-
sures (where two or more assessment measures are reported in the
same study, we will use the outcome measure that is listed first in
the hierarchy).
1. Objective measurements of cough/wheeze indices (cough or
wheeze recordings, cough receptor sensitivity, and airway hyper-
responsiveness).
2. Symptomatic measures, as assessed by parents or carers
(quality of life, Likert scale, Visual Analogue scale, level of
interference of respiratory symptoms, and diary cards).
3. Symptomatic measures, as assessed by clinicians (Likert
scale, Visual Analogue scale, level of interference of respiratory
symptoms, and diary cards).
Secondary outcomes
1. Proportion of participants who were not substantially
improved at follow-up (up to six months).
2. Mean difference in cough or wheeze indices (diary,
frequency, scores, and quality of life).
3. Proportion of participants with recurrent wheeze (within
six months of intervention).
4. Proportion of participants experiencing adverse effects of
the intervention.
5. Proportion of participants experiencing complications (e.g.
requirement for medication, or pneumonia).
We will select complete resolution of symptoms as the primary
outcome, as previously well children should completely recover
after an episode of acute bronchiolitis. As different studies may use
different outcome measurements to signify a cure, we will define
a hierarchy of outcomes, where we consider objective markers
superior to subjective measurements. Pneumonia and recurrent
wheeze (some with requiring repeat hospitalisation) have been
reported in cohort studies of bronchiolitis (Bailey 2009). Thus we
will consider readmission for a respiratory infection and recurrent
wheeze as important outcomes.
Search methods for identification of studies
Electronic searches
The Cochrane Airways Group’s Trials Search Co-ordinator will
perform the search; we will identify trials using the following
databases.
• The Cochrane Airways Group Register of Trials
• Cochrane Central Register of Controlled Trials
(CENTRAL)
• MEDLINE (Ovid)
• EMBASE (Ovid)
• ClinicalTrials.gov
The proposed MEDLINE strategy is listed in Appendix 1. We
will adapt this for use in the other databases. We will search all
databases from their inception to the present, and we will impose
no restriction on language of publication.
Searching other resources
We will check reference lists of the included studies and relevant
review articles for additional references. We will also contact au-
thors of identified trials, where appropriate, to seek further iden-
tification of other published and unpublished studies.
Data collection and analysis
Selection of studies
Two authors (GM, AC) will independently assess for inclusion all
the potential studieswe identify as a result of the search strategy.We
will resolve any disagreement through discussion or, if required,
adjudication sought from another author (PM).
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Data extraction and management
Two authors (GM, AC) will independently assess risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We will re-
solve any disagreements by discussion or by involving another au-
thor (PM). We will manage data in ReviewManager 5.1 (RevMan
2011), and according to recommendations in the Cochrane Hand-
book for Systematic Review of Interventions (Higgins 2011).
Assessment of risk of bias in included studies
We will assess the risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low or unclear.
Measures of treatment effect
For dichotomous variables, wewill calculate individual and pooled
statistics as odds ratios (ORs) with 95% confidence intervals (CIs).
For continuous outcomes measured on the same metrics, we plan
to calculate the individual and pooled statistics as mean differences
(MDs) with 95% (CIs). For continuous outcomes measured on
different metrics, we will combine data with a standardised mean
difference (SMD).
Unit of analysis issues
Cross-over and cluster-randomised trials are not appropriate for
the target population and therefore we will not include them.
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data when
necessary.
Assessment of heterogeneity
We will use the I2 statistic to measure heterogeneity among the
trials in each analysis. If we identify substantial heterogeneity we
will explore it by prespecified subgroup analysis. We will consider
levels of heterogeneity greater than 50% as substantial.
Assessment of reporting biases
Where we suspect reporting bias, we will attempt to contact study
authors and ask them to provide missing outcome data. Where
this is not possible, and the missing data are thought to introduce
serious bias, we will explore the impact of including such studies
in the overall assessment of results by conducting a sensitivity anal-
ysis. We plan to investigate publication bias by visually inspecting
a funnel plot if we are able to meta-analyse 10 or more trials in a
single outcome.
Data synthesis
We plan to create a Summary of findings table using the methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) and by using GRADEpro software. We plan to
include only the following outcomes: proportion of participants
who were not cured at follow-up; proportion readmitted for a
respiratory illness within six months; and serious adverse events.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Type of control arm (placebo/no treatment).
2. Severity (hospitalised versus non-hospitalised).
3. Macrolides versus other types of antibiotics.
4. Short (≤ 7 days) versus longer (> 7 days) courses of
antibiotics.
5. Antibiotics commencement (≤ 14 days or > 14 days of
onset of bronchiolitis).
6. Setting of study (affluent versus non-affluent setting).
Sensitivity analysis
We plan to remove studies considered to be at a high or unclear
risk of bias for methodological quality from themeta-analysis, and
examine any change in the summary statistic.
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1. exp Bronchiolitis/
2. Respiratory Syncytial Virus Infections/
3. bronchioliti$.tw.
4. RSV$.tw.
5. or/1-4
6. Cough/
7. Respiratory Sounds/
8. cough$.tw.
9. wheez$.tw.
10. post-viral$.tw.
11. post-acute$.tw.
12. co.fs.
13. Recurrence/
14. or/6-13
15. 5 and 14
16. post-RSV$.tw.
17. post-bronchiolit$.tw.
18. 15 or 16 or 17
19. exp Anti-Bacterial Agents/
20. antibiotic$.tw.
21. exp Macrolides/
22. (macrolide$ or azithromycin or clarithromycin or erythromycin or roxithromycin or spiramycin).tw.
23. (penicillin$ or amoxicillin or amoxycillin or ampicillin or benzylpenicillin or cloxacillin or dicloxacillin or flucloxacillin or piperacillin
or ticarcillin or sulbactam).tw.
24. (cephalosporin$ or cephalexin or cephaclor or cefaclor or cefepime or cefotaxime or cephamycin$ or cefotetan or cefoxitin or
cefmetazole or cefpirome or cefpodoxime or ceftazidime or ceftriaxone or cephamandole or cephazolin).tw.
25. (fluoroquinolone$ or ciprofloxacin or enoxacin or norfloxacin or ofloxacin or pefloxacin or fleroxacin or levofloxacin or moxi-
floxacin).tw.
26. (tetracycline$ or doxycycline or methacycline or minocycline).tw.
27. (amikacin or gentamicin or neomycin or netilmicin).tw.
28. (clindamycin or lincomycin).tw.
29. (chloramphenicol or amantadine or cotrimoxazole or trimethoprim).tw.
30. or/19-29
31. 18 and 30
32. exp Child/
33. exp Pediatrics/
34. exp infant/
35. exp adolescent/
36. (paediatric$ or pediatric$ or child$ or adolescen$ or infant$ or young$ or preschool$ or pre-school$ or newborn$ or new-born$
or neonat$ or neo-nat$).tw.
6Antibiotics for persistent cough or wheeze following acute bronchiolitis in children (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37. or/32-36
38. 31 and 37
We will combine this search with the Cochrane recommended filter to identify RCTs (Lefebvre 2011).
H I S T O R Y
Protocol first published: Issue 6, 2012
C O N T R I B U T I O N S O F A U T H O R S
The protocol was written by GM and AC. PM reviewed the protocol.
D E C L A R A T I O N S O F I N T E R E S T
All authors are involved in a RCT on the efficacy of azithromycin to reduce the respiratory burden of bronchiolitis in indigenous
children hospitalised with bronchiolitis (Chang 2011).
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